在一个高负担国家bedaquiline电阻的RT期刊论文SR电子T1出苗结核JF欧洲呼吸杂志JO欧洲呼吸ĴFD欧洲呼吸协会SP 2100621 DO 10.1183 / 13993003.00621-2021 A1 Chesov，埃琳娜A1 Chesov，杜米特鲁A1毛雷尔，188bet官网地址弗洛里安P. A1安德烈斯，SönkeA1 Utpatel，基督教A1 Barilar，伊万A1多尼卡，安娜A1莱曼，玛雅A1尼曼，斯特凡A1兰格，克里斯托夫A1 Crudu，瓦列A1 Heyckendorf，扬A1 MERKER，马蒂亚斯YR 2021 UL的http：//www.qdcxjkg.com/content/early/2021/08/19/13993003.00621-2021.abstract AB理由Bedaquiline已被归类为用于治疗耐多药结核病（MDR-TB）由世界卫生组织甲类药品然而新兴的全球性威胁的新MDR-TB治疗regimens.Objectives我们分析与治疗失败和死亡相关的预先存在的和基于bedaquiline MDR-TB治疗的新兴bedaquiline阻力和风险因素的有效性。方法在一个横截面队列研究，我们采用患者数据，全基因组测序（WGS）和结核分枝杆菌复合物（MTBC）的表型分型分离物。我们可以从谁在摩尔多瓦共和国2016年至2018年收到的所有bedaquiline MDR-TB患者的30.5％（203分之62）检索基线分离。这包括26个例对他们来说，我们也可以检索后续isolate.Measurements和主要结果在基线，所有MTBC菌株对bedaquiline。其中26例可用的基线和随访株，4/26（15.3％）患者窝藏，其获取下治疗bedaquiline耐药菌株，而1/26（3.8％）患者中重新感染了第二bedaquiline抗性菌株。治疗失败和死亡用空洞疾病（P = 0.011），并在含有与WGS-预测性方案在基线（P = 0.012，OR 1.92单位的增加，95％CI 1.15-3.21）的bedaquiline规定的任何另外的药物相关联的基于bedaquiline结论MDR-TB治疗需要的功能背景方案，以实现高治愈率，防止bedaquiline耐药性的发展。与bedaquiline新型耐多药结核病的治疗需要手稿最近已经接受了在欧洲呼吸杂志公布及时，全面的耐药性monitoring.FootnotesThis。据审稿，并通过我们的制作团队排版之前在这里其已接受的形式出版。 After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Chesov has nothing to disclose.Conflict of interest: Dr. Chesov has nothing to disclose.Conflict of interest: Dr. Maurer has nothing to disclose.Conflict of interest: Dr. Andres has nothing to disclose.Conflict of interest: Dr. Utpatel has nothing to disclose.Conflict of interest: Dr. Barilar has nothing to disclose.Conflict of interest: Dr. Donica has nothing to disclose.Conflict of interest: Dr. Reimann has nothing to disclose.Conflict of interest: Dr. Niemann reports grants from EXC 2167 Precision Medicine in Inflammation, grants from Leibniz Science Campus Evolutionary Medicine of the LUNG , grants from German Center for Infection Research, during the conduct of the study.Conflict of interest: Dr. Lange reports personal fees from Chiesi, Gilead, Janssen, Novartis, Oxfordimmunotec and Insmed, outside the submitted work.Conflict of interest: Dr. Crudu has nothing to disclose.Conflict of interest: Dr. Heyckendorf has nothing to disclose.Conflict of interest: Dr. Merker has nothing to disclose.